Supplementation with these can improve fat loss and has other cellular metabolism benefits, such as reducing C-reactive protein and slightly improving cholesterol levels: 1
B., Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimers disease: a 1-year, open-label pilot study with an 16-month caregiver extension
Mechanistic Evidence: Why This Might Work A 2025 narrative review explored whether tirzepatide could act as a disease-modifying therapy for lipedema (Viana et al., 2025)
FDA approves Ozempic (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease [Press release]
Overall, about one in five (22%) adults who are not currently taking GLP-1 drugs (88% of the public) say they would be interested in taking a GLP-1 drug to lose weight, including just 7% who say they would be very interested. This rises to four in ten (43%) among adults who are not currently taking a GLP-1 but report being diagnosed as overweight or obese in the past five years, and about one in four (27%) among those who say they have been diagnosed with diabetes or heart disease
, 2 , 423-428, Liu, J., Ng, T., Rui, Z., Ad, O., and Zhang, W
